2025-07-25 - Analysis Report
Okay, here's an analysis of Teladoc Health Inc (TDOC) based on the data you provided. The report is structured with numerical summaries followed by brief analyses, and is written in English.

**Report: Teladoc Health Inc (TDOC) Analysis**

**1. Performance vs. S&P 500 (VOO)**

*   **Ticker:** TDOC
*   **Company:** Teladoc Health Inc - A global leader in virtual care, offering telehealth solutions to patients and healthcare providers.
*   **TDOC Cumulative Return:** -64.52%
*   **VOO Cumulative Return:** 99.96%
*   **Divergence:**
    *   **Current Divergence:** -162.4
    *   **Max Divergence:** 456.6
    *   **Min Divergence:** -162.6
    *   **Relative Divergence:** 0.0

**Analysis:**

TDOC has significantly underperformed the S&P 500 (VOO) over the analyzed period. The current divergence is at its minimum, indicating a substantial negative difference in returns compared to the market. The Relative Divergence of 0.0 suggests TDOC's performance is near the bottom of its historical range relative to VOO.

**Alpha/Beta Analysis**

| Year       | CAGR    | MDD   | Alpha   | Beta    | Cap(B) |
|------------|---------|-------|---------|---------|--------|
| 2015-2017  | 76.0%   | 60.6% | 50.0%   | -0.0    | 6.1    |
| 2016-2018  | 128.0%  | 59.3% | 110.0%  | -0.0    | 8.7    |
| 2017-2019  | 176.0%  | 59.3% | 147.0%  | 0.4     | 14.7   |
| 2018-2020  | 237.0%  | 64.0% | 217.0%  | 0.1     | 35.1   |
| 2019-2021  | -83.0%  | 64.0% | -132.0% | 0.1     | 16.1   |
| 2020-2022  | -295.0% | 81.3% | -297.0% | 0.0     | 4.2    |
| 2021-2023  | -488.0% | 81.3% | -506.0% | -0.6    | 3.8    |
| 2022-2024  | -111.0% | 81.3% | -137.0% | -0.8    | 1.6    |
| 2023-2025  | -35.0%  | 72.9% | -86.0%  | -0.8    | 1.4    |

**Analysis:**

*   **CAGR:**  The Compound Annual Growth Rate shows significant declines in recent years, moving from very high growth to substantial losses.
*   **MDD:** Maximum Drawdown is consistently high, indicating significant volatility and potential for large losses.
*   **Alpha:**  The alpha values are largely negative in recent periods, suggesting TDOC has underperformed its benchmark on a risk-adjusted basis.
*   **Beta:** Beta values are close to zero or negative, indicating low correlation with the market.
*   **Cap:** Market cap has declined significantly.

**2. Recent Stock Price Movement**

*   **Current Price:** $8.20
*   **Previous Close:** $8.58
*   **Change:** -4.43%
*   **5-Day Moving Average:** 8.316
*   **20-Day Moving Average:** 8.33
*   **60-Day Moving Average:** 7.558

**Analysis:**

The stock price has recently decreased and is trading below both its 5-day and 20-day moving averages, suggesting a short-term downward trend.  The price is above 60-day moving average, which might signal a minor uptrend in the medium-term or indicate a potential area of support. The negative change in price from the previous close (-4.43%) indicates immediate negative pressure.

**3. Market Risk Indicators and Expected Return**

*   **MRI (Market Risk Indicator):** 0.3274 (Low Risk)
*   **RSI (Relative Strength Index):** 48.52
*   **PPO (Percentage Price Oscillator):** -0.4495
*   **Hybrid Signal:** Cash_69%_Sell 0.9% of holdings (14 shares - Caution - MRI:0.33)
*   **Recent (20-Day) Relative Divergence Change:** 0.0 (Short-term Decline)
*   **Expected Return:** -9736.8%

**Analysis:**

*   The MRI is in the "Low Risk" range, suggesting a relatively stable market environment (but this is a generalized market risk assessment, not specific to TDOC).
*   The RSI is near 50, indicating a neutral momentum.
*   The PPO is slightly negative, indicating that the short-term moving average is slightly below the long-term moving average.
*   The hybrid signal suggests a cautious approach, advising to sell a small portion of holdings and increase cash position, reflecting the uncertainty or downside risk.
*   The recent relative divergence change indicates a short-term decline relative to the comparison asset.
*   The **Expected Return is exceptionally negative**, suggesting that based on current trends, a long-term investment in TDOC could significantly underperform the S&P 500.
*   The price change from the previous close (-4.43%) indicate rapid change.

**4. Recent News & Significant Events**

*   **2025-07-23:** Major business developments, regulatory changes, or market events.
*   **2025-07-25:** Analyst discussions on performance and outlook in the context of industry trends and global economic factors.
*   **2025-07-24:** Notable stock volatility influenced by recent news, earnings reports, or executive actions.
*   **2025-07-22:** Market experts highlight risks and opportunities, advising monitoring of news and announcements.

**Analysis:**

The recent news indicates potential volatility and uncertainty surrounding TDOC. Investors should closely monitor company announcements, regulatory changes, and analyst reports to understand the factors influencing the stock's performance.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출        |
|------------|-------|-------------|
| 2025-05-01 | -0.53 | 0.63 B$     |
| 2024-10-31 | -0.19 | 0.64 B$     |
| 2024-08-01 | -4.92 | 0.64 B$     |
| 2024-04-26 | -0.49 | 0.65 B$     |
| 2025-05-01 | -0.49 | 0.65 B$     |

**Analysis:**

*   Teladoc Health Inc. has been reporting negative EPS (Earnings Per Share) values over the periods indicated. This suggests that the company is not currently profitable on a per-share basis.
*   Revenue has been relatively stable around $0.63B to $0.65B. While maintaining revenue is positive, the consistent negative EPS may indicate issues with cost management or other underlying financial challenges.
*   The -4.92 EPS in 2024-08-01 is particularly concerning, indicating a significant loss during that quarter. This anomaly could be due to one-time expenses or specific challenges faced during that period.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-03-31 | $0.63B | 68.73%        |
| 2024-12-31 | $0.64B | 70.50%        |
| 2024-09-30 | $0.64B | 71.94%        |
| 2024-06-30 | $0.64B | 70.73%        |
| 2024-03-31 | $0.65B | 69.89%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE      |
|------------|---------|----------|
| 2025-03-31 | $1.43B | -6.52%   |
| 2024-12-31 | $1.49B | -3.25%   |
| 2024-09-30 | $1.51B | -2.21%   |
| 2024-06-30 | $1.50B | -55.77%  |
| 2024-03-31 | $2.29B | -3.58%   |

**Analysis:**

*   **Revenue and Profitability:** The revenue has remained relatively consistent, with minor fluctuations around $0.63B to $0.65B. The profit margin is high, consistently around 70%, indicating efficient cost management relative to revenue.
*   **Capital and Profitability:** Equity has been declining, from $2.29B in 2024-03-31 to $1.43B in 2025-03-31, which could be concerning. The ROE (Return on Equity) is negative, indicating that the company is not generating profits from shareholders' investments. The significant drop in ROE to -55.77% in 2024-06-30 suggests a period of high loss relative to the equity.

**7. Comprehensive Analysis**

Based on the data provided, Teladoc Health Inc. (TDOC) presents a mixed picture with significant concerns:

*   **Underperformance:** TDOC has significantly underperformed the S&P 500, with a large negative divergence.
*   **Negative Financials:**  The company is currently unprofitable, as indicated by the negative EPS and ROE. The revenue is stable, and profit margins are high, but these factors are not enough to offset losses.
*   **Declining Equity:** The decline in equity is a concern.
*   **Volatility:** The stock has shown notable volatility, as indicated by MDD and recent news.
*   **Cautious Outlook:** Hybrid signal recommend cash position.
*   **Expected return:** Exceptionally negative expected return signals a longer-term downward trend.

**Recommendation:**

Given the significant underperformance, negative earnings, declining equity, and volatility, a cautious approach to TDOC is warranted. Investors should closely monitor company announcements, regulatory changes, and analyst reports to assess the potential for a turnaround. The negative expected return suggests that there are more promising opportunities elsewhere.
